“…186 Thus, in addition to providing sufficient quantities of the rare, in some instances, natural products themselves, we devoted time and effort toward analogue design, synthesis, and biological evaluation. Rich in molecular diversity and biological investigations, these value-added efforts yielded a number of promising compounds, including those within the antibiotic families of vancomycin (17, Figure 16l), 187,188 platensimycin (23, Figure 16m), [189][190][191][192][193][194][195][196] antibiotic BE-43472B (32, Figure 16o), 49,50 biyouyanagins A and B (127 and 33, Figure 16p), 114 dithiodiketopiperazines (326 and 327, Figure 16q), 161 antibiotic CJ-16,264 (39, Figure 16u), 109 and viridicatumtoxin B (37, Figure 16s). 106,107 Even maitotoxin (74, Figures 7 and 16t) did not escape our paradigm of analogue design, synthesis, and biological evaluation.…”